Opus Genetics (IRD) Free Cash Flow (2010 - 2026)
Opus Genetics (IRD) reported Free Cash Flow of -$12.7 million for Q1 2026, down 41.51% year-over-year from -$21.8 million in Q1 2025, and down 29.43% on a QoQ basis from -$9.8 million in Q4 2025.
Opus Genetics (IRD) has 17 years of Free Cash Flow data on file, last reported at -$12.7 million in Q1 2026.
- Quarterly Free Cash Flow fell 41.51% year-over-year to -$12.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$39.0 million (down 35.11% YoY) and the FY2025 annual result came in at -$35.3 million, down 37.84% from the prior year.
- Free Cash Flow declined to -$12.7 million in Q1 2026 per IRD's latest filing, from -$9.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $28.8 million in Q4 2022 and bottomed at -$12.7 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$5.7 million (2024), against an average of -$3.6 million.
- The widest annual swing landed in 2022, when Free Cash Flow jumped 609.94%; it then tumbled 837.31% in 2024.
- Tracing IRD's Free Cash Flow over 5 years: stood at $28.8 million in 2022, then slumped by 84.2% to $4.5 million in 2023, then tumbled by 263.54% to -$7.4 million in 2024, then sank by 32.2% to -$9.8 million in 2025, then declined by 29.43% to -$12.7 million in 2026.
- Per Business Quant, the three latest IRD Free Cash Flow figures stand at -$12.7 million (Q1 2026), -$9.8 million (Q4 2025), and -$6.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | -12.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.73 Mn |
| Mar 31, 2026 | -12.73 Mn |
| Dec 31, 2025 | -9.83 Mn |
| Dec 31, 2025 | -9.83 Mn |
| Sep 30, 2025 | -6.16 Mn |
| Sep 30, 2025 | -6.16 Mn |
| Jun 30, 2025 | -10.27 Mn |
| Jun 30, 2025 | -10.27 Mn |
| Mar 31, 2025 | -8.99 Mn |
| Mar 31, 2025 | -8.99 Mn |
| Dec 31, 2024 | -7.44 Mn |
| Dec 31, 2024 | -7.44 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Jun 30, 2024 | -7.29 Mn |
| Jun 30, 2024 | -7.29 Mn |
| Mar 31, 2024 | -5.72 Mn |
| Mar 31, 2024 | -5.72 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Sep 30, 2023 | -3.00 Mn |
| Sep 30, 2023 | -3.00 Mn |
| Jun 30, 2023 | 989,000.00 |
| Jun 30, 2023 | 989,000.00 |
| Mar 31, 2023 | -3.65 Mn |
| Mar 31, 2023 | -3.65 Mn |
| Dec 31, 2022 | 28.79 Mn |
| Dec 31, 2022 | 28.79 Mn |
| Sep 30, 2022 | -4.50 Mn |
| Sep 30, 2022 | -4.50 Mn |
| Jun 30, 2022 | -3.81 Mn |
| Jun 30, 2022 | -3.81 Mn |
| Mar 31, 2022 | -6.17 Mn |
| Mar 31, 2022 | -6.17 Mn |
| Dec 31, 2021 | -5.65 Mn |
| Dec 31, 2021 | -5.65 Mn |
| Sep 30, 2021 | -3.58 Mn |
| Sep 30, 2021 | -3.58 Mn |
| Jun 30, 2021 | -4.33 Mn |
| Jun 30, 2021 | -4.33 Mn |
| Mar 31, 2021 | -5.81 Mn |
| Mar 31, 2021 | -5.81 Mn |
| Dec 31, 2020 | -4.36 Mn |
| Dec 31, 2020 | -4.36 Mn |
| Sep 30, 2020 | -1.06 Mn |
| Sep 30, 2020 | -1.06 Mn |
| Jun 30, 2020 | -651,000.00 |
| Jun 30, 2020 | -651,000.00 |
| Mar 31, 2020 | -732,000.00 |
| Mar 31, 2020 | -732,000.00 |
| Dec 31, 2019 | 4.97 Mn |
| Dec 31, 2019 | 4.97 Mn |
| Sep 30, 2019 | -2.38 Mn |
| Sep 30, 2019 | -2.38 Mn |
| Jun 30, 2019 | -1.81 Mn |
| Jun 30, 2019 | -1.81 Mn |
| Mar 31, 2019 | -4.39 Mn |
| Mar 31, 2019 | -4.39 Mn |
| Dec 31, 2018 | -4.62 Mn |
| Dec 31, 2018 | -4.62 Mn |
| Sep 30, 2018 | -4.20 Mn |
| Sep 30, 2018 | -4.20 Mn |
| Jun 30, 2018 | -4.45 Mn |
| Jun 30, 2018 | -4.45 Mn |
| Mar 31, 2018 | -5.60 Mn |
| Mar 31, 2018 | -5.60 Mn |
| Dec 31, 2017 | -3.76 Mn |
| Dec 31, 2017 | -3.76 Mn |
| Sep 30, 2017 | -3.45 Mn |
| Sep 30, 2017 | -3.45 Mn |
| Jun 30, 2017 | -4.11 Mn |
| Jun 30, 2017 | -4.11 Mn |
| Mar 31, 2017 | -4.17 Mn |
| Mar 31, 2017 | -4.17 Mn |
| Dec 31, 2016 | -1.49 Mn |
| Dec 31, 2016 | -1.49 Mn |
| Sep 30, 2016 | -3.12 Mn |
| Sep 30, 2016 | -3.12 Mn |
| Jun 30, 2016 | -5.07 Mn |
| Jun 30, 2016 | -5.07 Mn |
| Mar 31, 2016 | -3.55 Mn |
| Mar 31, 2016 | -3.55 Mn |
| Dec 31, 2015 | -4.42 Mn |
| Dec 31, 2015 | -4.42 Mn |
| Sep 30, 2015 | -4.54 Mn |
| Sep 30, 2015 | -4.54 Mn |
| Jun 30, 2015 | -4.41 Mn |
| Jun 30, 2015 | -4.41 Mn |
| Mar 31, 2015 | -4.05 Mn |
| Mar 31, 2015 | -4.05 Mn |
| Dec 31, 2014 | -2.92 Mn |
| Dec 31, 2014 | -2.92 Mn |
| Sep 30, 2014 | -2.62 Mn |
| Sep 30, 2014 | -2.62 Mn |
| Jun 30, 2014 | -2.96 Mn |
| Jun 30, 2014 | -2.96 Mn |
| Mar 31, 2014 | -2.58 Mn |
| Mar 31, 2014 | -2.58 Mn |
| Dec 31, 2013 | -2.25 Mn |
| Dec 31, 2013 | -2.25 Mn |
| Sep 30, 2013 | -1.73 Mn |
| Sep 30, 2013 | -1.73 Mn |
| Jun 30, 2013 | -2.50 Mn |
| Jun 30, 2013 | -2.50 Mn |
| Mar 31, 2013 | -1.55 Mn |
| Mar 31, 2013 | -1.55 Mn |
| Dec 31, 2012 | -1.07 Mn |
| Dec 31, 2012 | -1.07 Mn |
| Sep 30, 2012 | -1.65 Mn |
| Sep 30, 2012 | -1.65 Mn |
| Jun 30, 2012 | -1.98 Mn |
| Jun 30, 2012 | -1.98 Mn |
| Mar 31, 2012 | -1.92 Mn |
| Mar 31, 2012 | -1.92 Mn |
| Dec 31, 2011 | -4.89 Mn |
| Dec 31, 2011 | -4.89 Mn |
| Sep 30, 2011 | -3.16 Mn |
| Sep 30, 2011 | -3.16 Mn |
| Jun 30, 2011 | -5.07 Mn |
| Jun 30, 2011 | -5.07 Mn |
| Mar 31, 2011 | -2.43 Mn |
| Mar 31, 2011 | -2.43 Mn |
| Dec 31, 2010 | -2.42 Mn |
| Dec 31, 2010 | -2.42 Mn |
| Sep 30, 2010 | -1.59 Mn |
| Sep 30, 2010 | -1.59 Mn |